Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 4/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272878 | 0.91 | KCNH2 (0.35) | KCNH2IRAK4CYP4F2CYP4A11PPARA | |
| SCHEMBL10272874 | 0.90 | KCNH2 (0.34) | KCNH2CYP4F2CYP4A11PPARAPPARG | |
| SCHEMBL16172520 | 0.90 | KCNH2 (0.35) | KCNH2CYP4F2CYP4A11PPARANPC1 | |
| SCHEMBL882894 | 0.89 | HSP90AA1 (0.38) | KCNH2CYP4F2CYP4A11PPARAPPARG | |
| SCHEMBL10273214 | 0.88 | BACE1 (0.34) | KCNH2CYP4F2CYP4A11PPARANPC1 | |
| SCHEMBL10273019 | 0.88 | LIPG (0.33) | KCNH2CYP4F2CYP4A11PPARAPPARG | |
| SCHEMBL882699 | 0.88 | NPC1 (0.35) | KCNH2CYP4F2CYP4A11PPARAPPARG | |
| SCHEMBL10273014 | 0.86 | KCNH2 (0.32) | KCNH2CYP4F2CYP4A11PPARANPC1 | |
| SCHEMBL10272867 | 0.86 | SMN1; SMN2 (0.47) | KCNH2CYP4F2CYP4A11NPC1LMNA | |
| SCHEMBL16164006 | 0.85 | KCNH2 (0.32) | KCNH2CYP4F2CYP4A11PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | KCNH2 2045/4885IRAK4 1726/4885CYP4F2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.